Details of Disease

General Information of Disease (ID: DIS50TOO)

• Disease Name: Nausea
• Disease Class: MD90: Nausea/vomiting
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS50TOO: Nausea
• ICD Code:
  ICD-11: ICD-11: MD90
  ICD-10: ICD-10: R11
  Expand ICD-10: L29,R11,T78
  Expand ICD-9: 698,787,787.0,995.3
• Disease Identifiers:
  MESH ID: D009325
  MedGen ID: 10196
  HPO ID: HP:0002018
  SNOMED CT ID: 422587007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 25 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aprepitant	DM053KT	Approved	Small molecular drug	[1]
Benzquinamide	DMU4D5Y	Approved	Small molecular drug	[2]
Buclizine	DMXKZT3	Approved	Small molecular drug	[3]
Cinnarizine	DM7U5QJ	Approved	Small molecular drug	[4]
Cyclizine	DM9G7BS	Approved	Small molecular drug	[5]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[6]
Dimenhydrinate	DM264B3	Approved	Small molecular drug	[7]
Diphenhydramine	DMKQTBA	Approved	Small molecular drug	[8]
Diphenidol	DMHPWOM	Approved	Small molecular drug	[9]
Dolasetron	DMMG26Z	Approved	Small molecular drug	[10]
Droperidol	DM0DXA8	Approved	Small molecular drug	[11]
Esomeprazole	DM7BN0X	Approved	Small molecular drug	[12]
Haloperidol	DM96SE0	Approved	Small molecular drug	[13]
Lorazepam	DM84ZXF	Approved	Small molecular drug	[14]
Metoclopramide	DMFA5MY	Approved	Small molecular drug	[15]
Omeprazole	DM471KJ	Approved	Small molecular drug	[16]
Ondansetron	DMOTQ1I	Approved	Small molecular drug	[17]
Palonosetron	DMBHMOX	Approved	Small molecular drug	[18]
Prochlorperazine	DM53SRA	Approved	Small molecular drug	[19]
Promazine	DMZAL7W	Approved	Small molecular drug	[20]
Promethazine	DM6I5GR	Approved	Small molecular drug	[21]
Scopolamine	DMOM8AL	Approved	Small molecular drug	[22]
Thiethylperazine	DMU3IET	Approved	Small molecular drug	[23]
Triflupromazine	DMKFQJP	Approved	Small molecular drug	[24]
Trimethobenzamide	DMPP4DT	Approved	Small molecular drug	[25]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lerisetron	DMOTCIU	Phase 3	Small molecular drug	[26]
Pancopride	DMIRYU9	Phase 3	Small molecular drug	[27]
Lintopride	DMSHGWN	Phase 2	Small molecular drug	[28]
ITASETRON	DMY1DFK	Phase 1	Small molecular drug	[29]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RG-12915	DMXV28I	Discontinued in Phase 3	Small molecular drug	[30]
DAT-582	DMY3M0J	Discontinued in Phase 2	Small molecular drug	[31]
YM-114	DML2IXO	Discontinued in Phase 2	Small molecular drug	[32]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3490).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7124).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7134).
• [4] Cinnarizine: A Contemporary Review. Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 2):1060-1068.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7151).
• [6] Dexamethasone FDA Label
• [7] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040519.
• [8] Diphenhydramine FDA Label
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7163).
• [10] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7172).
• [12] Esomeprazole FDA Label
• [13] Haloperidol FDA Label
• [14] Lorazepam FDA Label
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 241).
• [16] Omeprazole FDA Label
• [17] Ondansetron FDA Label
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7486).
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7279).
• [20] Promazine FDA Label
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7282).
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 330).
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7306).
• [24] Triflupromazine FDA Label
• [25] Trimethobenzamide FDA Label
• [26] Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001751)
• [28] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [29] ClinicalTrials.gov (NCT02259985) Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects. U.S. National Institutes of Health.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001786)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001226)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002741)